Research and Funding

Funding Opportunities

Notice of Intent to Publish a Funding Opportunity Announcement for Planning Grants for Alzheimers Disease Translational Centers for Predictive Drug Development (P20)

Funding Number: NOT-AG-14-009
Funding Type: NOT
Release Date: February 21, 2014
Expiration Date: January 1, 2020
Web Site:
Notice Intent Publish Funding Opportunity Announcement Planning Grants Alzheimer’s Disease Translational Centers Predictive Drug Development P20) Notice Number: NOT-AG-14-009 Key Dates Release Date: February 21, 2014 Estimated Publication Date Announcement: April 4, 2014  First Estimated Application Due Date:   June 4, 2014 Earliest Estimated Award Date: September 15, 2014  Earliest Estimated Start Date: September 15, 2014 Related Announcements None Issued National Institute Aging NIA) Purpose Key recommendations the NIH Alzheimer’s Disease AD) Research Summit 2012: Path Treatment Prevention related overcoming underlying causes failure AD drugs the clinic attaining goal precision medicine AD treating right patient the right drug the right stage the disease) called development broad capabilities infrastructure quantitative systems pharmacology QSP) understand impact drugs organisms a precise predictive manner order  determine dosing, reduce toxicity, enable rational drug repurposing development combination therapies.   QSP an emerging model-based, data-driven approach drug development integrates systems biology pharmacology breaks decisively a ldquo;one-gene, one-receptor, one-mechanism” approach favor a network-centric view drug targets drug action.  general framework the development implementation a QSP approach been provided the NIH QSP Workshop Group  response the above recommendations in order achieve key research milestones the National Plan Address Alzheimer’s Disease ), National Institute Aging the NIH plans establish to translational centers will apply QSP approaches AD drug discovery development.  integrating multidimensional multiscale data analysis mathematical modeling empirical testing throughout preclinical early clinical development, translational center initiative aid validation novel targets through clinical proof mechanism, design selection candidate therapeutics, development predictive biomarkers efficacy toxicity, the selection patients most likely respond single therapeutic agents combinations agents.  translational centers initiative planned fiscal year 2016; will the U54 cooperative agreement mechanism a multi-component specialized center. Center(s) have/develop following capabilities: conduct quantitative analysis the effects small molecules biologic drugs therapeutic  targets across multiple scales complexity investigate origins variability drug response the single-cell, organ patient level arise differences the level the proteome, genome environment generate and/or exploit diverse ldquo;omic” data collected  humans various animal models identify translatable pharmacodynamic biomarkers enable modeling drug response determinants distinct patient populations develop multi-scale computational models pharmacological mechanism bridge divide between cell-level biochemical models organism-level PK/PD models develop systems approaches comprehensive systematic failure analysis during preclinical clinical drug development enable rapid broad sharing data, analytical research tools models prior publication translational center(s) bring together expertise various high-throughput lsquo;omic’ technologies, acquisition, integration analysis multiscale data, mathematical modeling, structural biology, medicinal chemistry, chemo-informatics, PK/PD modeling, pharmacology, trial design failure analysis.   Realizing challenges bringing together groups required expertise develop competitive center application, NIA intends support P20 planning grants will facilitate development necessary multi-institutional and/or multi-sector academia, industry, non-profit organizations) collaborations partnerships. Notice encourages investigators institutions organizations relevant expertise capabilities begin consider developing relevant collaborations/partnerships apply a planning grant. intended planning grant FOA utilize P20 activity code. Details the FOA provided below. Research Initiative Details Planning Grant P20) FOA support planning the development a full application a multi-institutional and/or multi-sector translational center will fulfill above-described programmatic goals. onetime, 1 year awards support variety planning activities necessary develop relevant collaborations capabilities, it not support direct research activities. The direct costs budget the planning grant P20) limited 200,000. NIA anticipates awarding to 4 planning grants depending the quality the planning grant applications availability funds. APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: Suzana Petanceska, Ph.D. National Institute Aging NIA) Telephone: 301-496-9350 Email: nbsp;